Cbl Ubiquitin Ligases Control B Cell Exit from the Germinal-Center Reaction by Li, X et al.
This is a repository copy of Cbl Ubiquitin Ligases Control B Cell Exit from the 
Germinal-Center Reaction.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/138174/
Version: Accepted Version
Article:
Li, X, Gadzinsky, A, Gong, L et al. (9 more authors) (2018) Cbl Ubiquitin Ligases Control B 
Cell Exit from the Germinal-Center Reaction. Immunity, 48 (3). 530-541.e6. ISSN 
1074-7613 
https://doi.org/10.1016/j.immuni.2018.03.006
(c) 2018, Elsevier Inc. This manuscript version is made available under the CC BY-NC-ND 
4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 
(CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long 
as you credit the authors, but you can’t change the article in any way or use it commercially. More 
information and the full terms of the licence here: https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
1 
  
Cbl ubiquitin ligases control the exit checkpoint of the germinal center 
reaction 
 
Xin Li1,2, Adeline Gadzinsky1, Haijun Tong1,2, Liying Gong1,3, Virginie Calderon1, Yue 
Li1,4, Daisuke Kitamura5, Ulf Klein6, Wallace Y. Langdon7, Fajian Hou8, and Yong-Rui 
Zou9 & Hua Gu1,2,3,10 
 
 
1Montreal Clinical Research Institute, Montreal, Quebec H2W 1R7, Canada 
2Department of Microbiology and Immunology, University of Montreal, Montreal, 
Quebec H3T 1J4, Canada 
3Division of Experimental Medicine, McGill University, Montreal, Quebec H3A 0G4, 
Canada 
4Department of Microbiology and Immunology, McGill University, Montreal, Quebec 
H3A 0G4, Canada 
5Research Institute for Biomedical Sciences, Tokyo University of Sciences, Noda, 
Chiba 162-8601, Japan 
6 Leeds Institute of Cancer and Pathology, School of Medicine, University of Leeds, 
Leeds LS97TF, United Kingdom 
7 School of Biomedical Sciences, University of Western Australia, Crawley, Western 
Australia 6009, Australia 
8Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 
Shanghai 200031, China 
9The Feinstein Institute for Medical Research, Manhasset, New York 11030, USA 
10Lead Contact 
 
Correspondence: hua.gu@ircm.qc.ca 
 
 
 
2 
Highlights 
Antibody affinity maturation depends on B cell intrinsic Cbls 
 
Cbls control the clonal expansion of high B cells in GCs 
 
Cbls are dynamically regulated in GC DZ and LZ B cells and downregulated upon 
sensing strong CD40 and BCR signaling 
 
Cbls prevent nuclear Irf4 accumulation by ubiquitinating Irf4 
 
 
In Brief 
How B cells are retained in the germinal centers (GC) for affinity driven selection 
remains unclear. Gu and colleagues demonstrate that CBL-Irf4 constitutes an 
ubiquitination-dependent regulatory cascade to control the clonal expansion of B 
cells in GCs until high affinity BCRs are acquired. 
 
 
SUMMARY 
Selective expansion of high affinity B cells in the germinal center (GC) is a key event 
of the antibody affinity maturation. It remains elusive how GC B cells with improved 
affinity decide to continue affinity-driven selection or differentiate into plasma cells 
(PCs) or memory B cells. Here we found that ablation of E3 ubiquitin ligases Cbl and 
Cbl-b (Cbls) impaired clonal expansion of high affinity GC B cells due to the earlier 
exit from the GC cycle. Cbls were highly expressed in GC light zone (LZ) as compared 
to dark zone (DZ) B cells and impeded PC differentiation by promoting Irf4 
ubiquitination. CD40 and BCR stimulation reduced Cbl proteins and concomitantly 
increased Irf4 expression. Increased Irf4 expression alone was sufficient to abolish 
GC affinity selection. Thus, by promoting Irf4 ubiquitination Cbls control a GC 
program that prevents high affinity B cells from prematurely exiting the GC cycle to 
ensure affinity-driven clonal expansion. 
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INTRODUCTION  
Production of high affinity antibodies is central to T cell-dependent humoral 
immunity against pathogens and occurs in germinal centers (GC) through a process 
termed antibody affinity maturation (Liu et al., 1989; Rajewsky, 1996). Upon 
encounter with antigen, activated B cells enter GCs to undergo clonal expansion and 
somatically mutate their B-cell antigen receptor (BCR) genes via activation-induced 
cytidine deaminase (AID)-mediated somatic hypermutation (SHM) in the 
anatomically distinct dark zone (DZ) (Allen et al., 2007; Berek et al., 1991; Jacob et 
al., 1991; Muramatsu et al., 2000; Victora and Nussenzweig, 2012). B cells with a 
mutant BCR then migrate to the light zone (LZ) to compete for the antigen presented 
by follicular dendritic cells (FDC) and the help from T follicular helper (Tfh) cells 
(Allen et al., 2007; Crotty, 2011; Ramiscal and Vinuesa, 2013; Shulman et al., 2014; 
Victora and Nussenzweig, 2012). Higher affinity BCRs have advantages to compete 
for the antigen, allowing B cells to receive more help such as CD40L stimulation 
from Tfh cells (Gitlin et al., 2014; Meyer-Hermann et al., 2012; Schwickert et al., 
2007; Victora and Nussenzweig, 2012). Surviving GC B cells with improved affinity 
to the antigen may terminate the GC B cell fate and differentiate into memory B cells 
or plasma cells (PCs), or migrate back to the DZ for a further round of SHM and 
clonal expansion (Bannard and Cyster, 2017; De Silva and Klein, 2015; Dufaud et al., 
2017; Mesin et al., 2016; Shlomchik and Weisel, 2012; Victora and Nussenzweig, 
2012). The spatial and temporal circulation between the GC DZ and LZ enables B 
cells with higher affinity BCRs being preferentially expanded and selected to enter 
the memory or PC pool.  
 
Given the critical role of such a GC inter-zonal circulation in the generation and 
selection of high affinity BCR-expressing B cells, much effort has been invested to 
understand the mechanisms by which B cells are instructed to stay in or exit the DZ-
LZ cycle to become memory B cells or PCs. At the transcriptional level, maintenance 
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of the GC B cell fate is controlled by GC B cell promoting transcription factors such 
as Bcl6 (Basso and Dalla-Favera, 2012). In contrast, the identity of PCs depends on 
the transcription factors Blimp1 and Irf4 (Klein et al., 2006; Sciammas et al., 2006; 
Shapiro-Shelef et al., 2003). These two groups of transcription factors 
antagonistically regulate each other and dictate the steady-state distinctive 
characteristics of GC B cells and PCs, respectively (Nutt et al., 2015; Shapiro-Shelef 
and Calame, 2005). In addition to these transcription factors, Myc, Foxo1, and NFNB 
have been reported to provide additional layers of regulation during the GC reaction 
(Calado et al., 2012; De Silva and Klein, 2015; Dominguez-Sola et al., 2015; 
Dominguez-Sola et al., 2012; Heise et al., 2014; Inoue et al., 2017; Sander et al., 
2015). Inactivation of NFNB, or Myc in GC B cells results in the collapse of the GCs, 
due to the impaired cycling of LZ B cells to the DZ. Foxo1 is essential for the DZ 
phenotype; mice with deletion of Foxo1 in GC B cells have only LZ cells. However, 
the molecular mechanisms that sense BCR affinity cues in GC B cells and instructs B 
cells to continue the DZ and LZ cycle or to initiate the differentiation program to PCs 
are not fully defined.  
 
Cbl and Cbl-b (Cbls) are members of the Cbl family of E3 ubiquitin ligases expressed 
in hematopoietic cells (Huang and Gu, 2008). In B cells, they play a crucial role in the 
induction of immune tolerance, possibly by regulating the negative selection of 
autoreactive B cells (Kitaura et al., 2007). Inactivation of Cbls using the Cd19-cre 
allele results in a moderate increase in IgM and reduction in IgG isotypes of T-cell 
dependent antibody responses (Kitaura et al., 2007). Here, we examined the 
function of Cbls in the GC reaction. We found that CBLs are essential for the 
selection of high affinity GC B cells and antibody affinity maturation. In GCs, the 
expression of Cbl proteins is minimal in DZ B cells and significantly increased in LZ 
B cells. They suppress Irf4 expression by promoting Irf4 ubiquitination. Ablation of 
Cbls in GC B cells increases the expression of Irf4, leading to impaired clonal 
expansion of high affinity B cells and expedited GC differentiation, despite normal 
SHM and DZ-LZ cycling of GC B cells. Consistent with this result, ectopic expression 
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of Irf4 alone or inactivation of the ubiquitin ligase activity of Cbls is sufficient to 
recapitulate the GC phenotypes found in Cbls mutant mice. Thus, our data indicate 
that B cell-intrinsic Cbls-Irf4 axis constitutes an ubiquitination dependent 
regulatory cascade that temporally controls GC B cells to stay in the DZ-LZ cycle 
until the acquisition of high affinity BCRs.  
 
RESULTS 
Expression patterns of Cbls in B cell subsets and the GC reaction  
To evaluate whether Cbl proteins regulate T-dependent antibody response, we first 
examined the expression patterns of Cbl and Cbl-b in naïve and GC B cells. We found 
that decreased amounts of both Cbl and Cbl-b mRNA in GC B cells as compared to 
naïve B cells; however, GC B cells expressed higher amounts of Cbl and Cbl-b 
proteins as compared to naïve B cells (Figures 1A, 1B and S1A). The marked 
alteration seemed to be a GC phenomenon, since activation of B cells with anti-IgM 
or anti-CD40 induced only a mild increase or a decrease in both Cbl and Cbl-b 
proteins, respectively (Figure S1B). Within GC B cell populations, the LZ GC B cells 
possessed significantly more Cbl and Cbl-b protein but not mRNA compared to the 
DZ B cells (Figures 1C, 1D, S1C and S1D). These results indicate that Cbl proteins 
are post-transcriptionally and dynamically modulated during the GC reaction. 
  
Ablation of Cbl proteins in GC B cells impairs antibody affinity maturation  
We then generated Cblfl/fl Cbl-b-/- IgCJ-cre transgenic (tg) mice in which the IgCJ-cre 
allele drove Cre recombinase expression in GC B cells so that only GC B cells 
(perhaps some activated B cells) carried the Cbl and Cbl-b double null (termed here 
as Cbl-/- Cbl-b-/-) mutation, whereas other cells of the mice harbored the germline 
cbl-b mutation (Casola et al., 2006; Chiang et al., 2000; Naramura et al., 2002). 
Ablation of Cbl and Cbl-b proteins in GC B cells was confirmed by Western blot 
analysis and immunofluorescent staining (Figures S2A and S2B). Inspection of Cbl-
/- Cbl-b-/- mice revealed normal development of B cells (Figures S2C and S2D). 
Compared to WT mice, the mutant mice produced similar levels of total anti-NP 
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(NP30) antibodies of IgM and IgG1 isotypes initially, after immunization with (4-
Hydroxy-3-Nitrophenyl)Acetyl-Keyhole Limpet Hemocyanin (NP-KLH); however, 
they displayed a significantly lower level of IgG1 at day 28 (Figure 2A). In addition 
to the antibody titer, Cbl-/- Cbl-b-/- mice exhibited impaired antibody affinity 
maturation, as the level of anti-NP4 as well as the ratio of high affinity anti-NP (NP4) 
vs total anti-NP (NP30) IgG1 was severely impaired in the mutant mice compared to 
the WT controls (Figures 2B and 2C). In addition, the mutant mice possessed 
slightly more IgM antibody-secreting cells (ASCs) against NP30 antigen. In contrast, 
they had markedly reduced numbers of total (anti-NP30) as well as high affinity 
(anti-NP4) IgG1 ASCs relative to their WT counterparts (Figure 2D). The 
discrepancy between the serum anti-NP30 antibody titers at day 14 (Figure 2A) and 
the numbers of anti-NP30 APCs at day 12 (Figure 2D) could be explained by that the 
formers reflect the accumulative antibodies produced by BM and peripheral ASCs, 
whereas the latters counted only the splenic ASCs present at the given date. 
 
In T-cell dependent immune responses, ASCs or PCs are mostly derived from GC B 
cells. To examine whether the Cbl-/- Cbl-b-/- mutation affected the GC reaction, we 
analyzed the kinetics of GC B cell development during the course of immunization. 
At day 8 after immunization, WT and Cbl-/- Cbl-b-/- mice developed equal 
percentages of GC B cells; however, while WT mice exhibited a peak GC 
development at day 11 and declined GC B cell numbers thereafter, the mutant mice 
had a slow increase in GC B cells up to day 22 (Figure 2E). The altered kinetics of GC 
B cell development in the mutant mice could be partly attributed to a combinatory 
effect of expedited differentiation and reduced apoptosis, because Cbl-/- Cbl-b-/- GC B 
cells generated more plasma cells (see below) and expressed a lower number of 
active Caspase positive cells compared to the WT controls, respectively (Figure 2F). 
Cell cycle analysis revealed similar proportions of G1, S, and G2/M phase cells, 
indicating that the proliferation of GC B cells was not affected by the Cbl-/- Cbl-b-/- 
mutation (Figure S3A). In addition to the altered kinetics of GC B cell expansion, the 
mutant mice had a markedly lower number of GC B cells expressing a high affinity 
cell surface IgG1 BCR against NP antigen relative to the WT mice throughout the 
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course of immunization (Figure 2G). The influence on high affinity BCR-expressing 
GC B cells was not caused by IgCJ-Cre tg and appeared to be redundant between Cbl 
and Cbl-b, because IgCJ-Cre tg mice had normal numbers of total and high affinity 
GC B cells, and ablation of Cbl or Cbl-b alone exhibited only a relatively mild effect 
on the numbers of high affinity NP-binding GC B cells compared to the Cbl-/- Cbl-b-/- 
mutants (Figure S3B and S3C). Together, our results indicate that Cbl proteins 
control antibody affinity maturation and to less extent the total antibody 
production. In addition, the data also suggest that this regulation occurs at the stage 
of GC B cells. 
 
Cbl proteins regulate GC selection for high affinity BCR-expressing B cells 
Deficiency in generating high affinity antibody producing cells could be a result of 
impaired SHM or lack of selection for high affinity B cells in the GC. To distinguish 
these two possibilities, we first analyzed SHM in IgH genes in GC B cells. We isolated 
IgO1+ GC B cells from NP-KLH immunized mice by FACS sorting at day 14 
postimmunization and examined SHM in Ig VH186.2 by DNA sequencing according 
to the previous publication (Dominguez-Sola et al., 2012) (Figure S4A). We found 
that while all (20/20) VH186.2 genes isolated from WT GC B cells carried at least one 
mutation (range: 1-15 mutations), about ~85% (17/20) of VH186.2 genes from Cbl-/- 
Cbl-b-/- GC B cells were mutated (range: 1-9 mutations) (Figure 3A and 3B). In 
addition, VH186.2 genes from WT GC B cells carried five replacement 
mutations/clone and 65% (13/20) of VH186.2 genes harbored a tryptophan to 
leucine mutation at position 33 (W33L) (Figure 3C), a mutation known to encode a 
high affinity BCR to NP when paired with a IgO1 light chain. In contrast, VH186.2 
genes from Cbl-/- Cbl-b-/- B cells possessed merely two replacement mutations per 
clone on average and only 15% (3/20) of clones carried a W33L mutation. Analysis 
of the replacement vs silent mutations (R/S ratio) in VH186.2 genes revealed that 
while the VH genes from WT GC B cells had undergone strong selection (R/S = 5), 
those from Cbl-/- Cbl-b-/- B cells exhibited an R/S ratio equivalent to that expected 
for the random mutation (R/S = 2) (Figure 3D). The frequencies of the silent 
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mutations in VH186.2 genes were comparable between WT and Cbl-/- Cbl-b-/- B cells 
(Figure 3B), indicating that the SHM per se is not affected by the Cbl-/- Cbl-b-/- 
mutation. To ascertain that the above phenomenon in VH186.2 genes indeed 
reflected that in NP-specific BCRs, we also compared SHM in VH186.2 genes isolated 
from NP38-binding GC B cells. Consistent with that observed in IgO1+ GC B cells, the 
number of VH186.2 genes carrying a W33L mutation was also significantly reduced 
in the mutant NP-specific GC B cells compared to WT controls (Figure S4B and 
S4C).  
 
To directly examine whether Cbls regulated cellular selection of high affinity BCR-
expressing cells inside GCs, we compared the kinetics of high affinity NP (NIP5) and 
total NP (NP38)-binding GC B cell development at different time points upon NP-KLH 
immunization (Figure 3E). At day 8 after immunization, WT mice had 
approximately 20% of NIP5-binding and 31% NP38-binding GC B cells, indicating 
that approximately 65% of total NP-specific GC B cells express a high affinity BCR as 
defined by NIP5-binding capability. By day 14, the ratio of NIP5 vs NP38-binding GC B 
cells increased to more than 90%, indicating that the high affinity NP specific B cell 
population is selectively expanded within total NP specific GC B cells. In contrast to 
WT mice, Cbl-/- Cbl-b-/- mice possessed relatively lower numbers of NIP5 and NP38-
binding GC B cells at day 8 (average 5% and 9%, respectively), equivalent to 
approximately 61% of NIP5-binding cells among total NP38-binding cells. However, 
by day 14 this ratio only increased slightly to less than 70%, indicating that the 
selection for NIP5-binding cells is severely impaired in the mutant mice. 
 
Taken together, the above data demonstrate that Cbls are required for the selection 
of high affinity BCR expressing B cells during GC reaction. However, they appear to 
be dispensable for the regulation of SHM in GC B cells. 
 
The Cbl-/- Cbl-b-/- mutation expedites GC B cell differentiation to PCs 
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During affinity maturation, GC B cells undergo multiple cycles of proliferation and 
SHM in the DZ and selection and differentiation to PCs and memory B cells in the LZ 
(Meyer-Hermann et al., 2012; Victora et al., 2010). Disruption of these cycles may 
impair affinity-driven selection of GC B cells (Allen et al., 2007; Mesin et al., 2016). 
To understand the mechanisms by which Cbl proteins regulate GC affinity selection, 
we examined whether the Cbl-/- Cbl-b-/- mutation affected the development of DZ 
and LZ GC B cells or the differentiation dynamics of GC B cells to PCs. The DZ and LZ 
architecture and B cell populations in the immunized Cbl-/- Cbl-b-/- mice appeared to 
be normal (Figure S5A and S5B). However, B220+ GL7hi Fashi GC B cells in Cbl-/- Cbl-
b-/- mice possessed significantly more plasma cell precursor-like cells that 
downregulated Bcl6 and slightly upregulated CD138 (Figure S5C), suggesting that 
the Cbl-/- Cbl-b-/- mutation expedites GC B cells to PC differentiation.  
 
To examine whether the Cbl-/- Cbl-b-/- mutation affected GC B cell differentiation, we 
performed BrdU labeling experiment to determine whether GC B cell development 
into PCs was increased in the mutant mice. At day 12 after immunization, in both 
WT and Cbl-/- Cbl-b-/- mice approximately 90% of GC B cells incorporated BrdU after 
twenty-four hours of BrdU labeling (Figure S6A), consistent with previous findings 
that GC B cells are vigorously proliferating. In contrast, the mutant mice generated 
50% more BrdU+ PCs as compared to WT mice (17% vs 11%) during the same 
period, which was equivalent to the genesis of 6,000 PCs/hour/spleen in Cbl-/- Cbl-b-
/- mice compared to 4,000/hour/spleen in WT controls (Figures 4A and 4B). These 
BrdU+ PCs were mostly newly generated from NP-KLH activated B cells, rather than 
derived from spontaneous immune responses or existing PC and plasma blast 
proliferation, because twenty-four hours BrdU labeling of un-immunized WT and 
Cbl-/- Cbl-b-/- mice produced only 1-2% of BrdU+ PCs (Figure S6B). Given that the 
mutant mice had less GC B cells than WT controls at day 12 after immunization 
(Figure 2E), increased PC genesis in Cbl-/- Cbl-b-/- mice is consistent with the idea 
that Cbl proteins are responsible for retaining GC B cells in the DZ-LZ cycle and 
preventing them from differentiation into PCs. 
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To directly assess the effect of Cbls on the fate choice of B cells in developing GCs in 
the context of affinity selection, we examined the development of high affinity NP-
specific GC B cells and PCs upon inducible ablation of Cbls. We transferred B cells 
from ER-Cre tg (Control) or Cblfl/fl Cbl-b-/- ER-Cre tg (termed Cbl-/- Cbl-b-/-ERCre) mice 
into PMT recipient mice and immunized the chimeric mice with NP-KLH so that the 
donor B cells could enter and initiate GC reaction. We then deleted Cbls by 
tamoxifen at day 7 after immunization, at which stage about 60% of NP specific B 
cells already acquired a high affinity BCR (Figure 3E), and analyzed NIP5-binding GC 
B cells and PCs at day 12 by flow cytometry. Mice ablated Cbls showed a marked 
reduction in the number of NIP5-binding GC B cells; however, the total number of GC 
B cells was only moderately reduced compared to that in controls (Figure 4C). 
Consistently, Cbl ablation led to significant increases in the numbers of total and 
NIP5-binding PCs relative to mice without Cbl deletion (Figure S6C and S6D). Given 
that high affinity PCs are mostly generated through GC reaction, concomitant 
reduction in NIP5-binding GC B cells and increase in NIP5-binding PCs supports the 
idea that loss of Cbls facilitates the high affinity GC B cells to choose the PC fate and 
differentiate into PCs. 
 
Differentiation of GC B cells to PCs is influenced by CD40 and the BCR (Krautler et 
al., 2017). To determine whether Cbl control the PC differentiation program via 
differentiation to PCs in vitro. Stimulation of Cbl-/- Cbl-b-/- naïve B cells from Cblfl/fl 
Cbl-b-/- Mb1-Cre tg mice with either membrane-bound CD40L expressed on 40LB 
feeder cells or soluble anti-CD40 generated significantly more B220-CD138+ and 
B220+ CD138+ cells (Figures 4D and S6E). These cells appeared to be PCs or plasma 
blast-like cells because they expressed intracellular Ig, upregulated Irf4, and 
downregulated Bcl6 (Figure S6F). Similarly, culture of freshly isolated Cbl-/- Cbl-b-/- 
GC B cells on CD40LB feeders also generated more B220+CD138+ plasma blast-like 
cells relative to WT controls (Figure 4E). In contrast, anti-IgM stimulation alone 
produced comparable numbers of B220+CD138+ cells from the mutant and WT B 
cells, suggesting that BCR signaling induced PCs is not enhanced by the Cbl-/- Cbl-b-/- 
11 
mutation (Figure S6E). Neither CD40 nor BCR-induced proliferation of B cells was 
affected by the Cbl-/- Cbl-b-/- mutation (Figure S6G). Together, these data indicate 
that ablation of Cbl proteins does not affect CD40 or BCR induced GC B cell 
proliferation but rather expedites CD40-induced B cell differentiation into PCs.  
 
The frequency of B cell differentiation into PCs increases with each cell division 
cycle (Hasbold et al., 2004). To study the influence of the Cbl-/- Cbl-b-/- mutation on 
PC differentiation in each cell division, we labeled naïve WT and Cbl-/- Cbl-b-/- B cells 
with CellTrace, stimulated them with 40LB feeder cells, and then examined PC 
differentiation in different divisions of proliferating B cells by monitoring both the 
Irf4 and CD138 expression. Consistent with the above finding, ablation of Cbls did 
not affect the rate of B cell division; however, the mutant B cells generated 50% 
more Irf4hi cells than WT controls in the third and fourth cell division (Figure 4F). A 
similar increase in CD138+ cells was also found in the Cbl-/- Cbl-b-/- compared to the 
WT B cell culture (Figure S6H). These findings together indicate that, while still 
maintaining vigorous cell division, loss of Cbls induces more B cells to exit B cell fate 
and turn on the PC differentiation program in each cell division. 
 
The Cbl-/- Cbl-b-/- mutation enhances the expression of Irf4 protein but not 
mRNA in GC B cells 
The identities of GC B cells and PCs are respectively controlled by Bcl6 and Blimp1. 
Irf-4 provides another layer of regulation by repressing Bcl6 and promoting Blimp1 
gene transcription (Basso and Dalla-Favera, 2015). To elucidate how the Cbl-/- Cbl-b-
/- mutation affected the GC B cell differentiation program, we compared the gene 
expression profiles of GC B cell and PC identity genes in WT and Cbl-/- Cbl-b-/- GC B 
cells at day 12 after immunization. RNA-seq analysis revealed that the expression of 
~900 genes was decreased and ~50 genes increased for at least two-fold in Cbl-/- 
Cbl-b-/- GC B cells as compared to WT controls (Figure S7A); however, this analysis 
revealed a slightly lower expression of several known GC B cell or PC identity genes 
such as Bcl6, Bach2, Irf4, and Aicda (Figure S7B). qPCR analysis confirmed that 
while the expression of Bcl6, Bach2, and Aicda was slightly reduced, the expression 
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of PC identity gene Irf4 was not increased in the mutants compared to WT GC B cells 
(Figure 5A). Despite this observation, the mutant GC B cells elevated the expression 
of multiple genes related to RNA processing and protein translation and secretion 
involved in PC function (Figures 5B and S7A), suggesting that some mutant B cells 
already initiate the PC differentiation program.  
 
To determine whether the Cbl-/- Cbl-b-/- mutation influenced the PC development 
program at the protein level, we examined CD40 and BCR signaling, as well as the 
levels of Bcl6 and Irf4 proteins in GC B cells. We found that activation of CD40 or 
BCR signaling pathways, including canonical NF-NB, AKT, S6K, and ERK, was not 
altered by the Cbl-/- Cbl-b-/- mutation (Figures ES1A-C). In contrast, the expression 
of Irf4 protein was markedly increased in freshly isolated mutant GC B cells 
compared to the controls (Figure 5C). To gain insight into the expression of Irf4 and 
Bcl6 during GC B cell differentiation at the single cell level, we examined 
intracellular Bcl6 and Irf4 in developing GC B cells by flow cytometry. In WT mice, a 
majority of GC (B220+ Fashi GL7hi) B cells expressed a high level of Bcl6 (Bcl6hi), 
whereas only approximately 10% of GC B cells exhibited reduced level of Bcl6 
(Bcl6lo) and about half of them simultaneously had more Irf4 protein (Bcl6lo Irf4hi), a 
population that might represent PC precursors (Figure 5D). Stimulation of CD40 
and BCR for 3 hours significantly increased the Bcl6lo Irf4hi subset to ~40% of the 
total GC B population (Figure 5E). In contrast to WT mice, Cbl-/- Cbl-b-/- mice 
already possessed significantly more (15%) Bcl6lo Irf4hi GC B cells in the absence of 
any stimulation, and CD40 and BCR stimulation boosted the Bcl6loIrf4hi population 
to more than ~50% of total GC B cells (Figures 5D and 5E). Western blot analysis 
confirmed that Irf4 protein was indeed elevated in Cbl-/- Cbl-b-/- GC B cells compared 
to WT cells with or without CD40 and BCR stimulation (Figure 5F). This result, 
along with the mRNA expression data, indicates that Cbl proteins do not affect the 
major signaling pathways downstream of CD40 or the BCR. Instead, they may retain 
GC B cells fate by suppressing the expression of Irf4 protein rather than Irf4 
transcription.  
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Cbls promote nuclear Irf4 ubiquitination and degradation 
Cbl proteins are known cytosolic E3 ubiquitin ligases, whereas Irf4 is a transcription 
factor that functions mainly in the nucleus. We therefore examined at which 
subcellular location Cbl proteins exert their regulatory function on Irf4. Confocal 
microscopy analysis showed that Irf4 was barely detectable in freshly isolated WT 
GC B (B220+ GL7hi Fashi) cells and significantly accumulated in the nucleus after 
CD40 and BCR stimulation. In contrast, a significant proportion of Cbl-/- Cbl-b-/- GC B 
cells already possessed a high level of nuclear Irf4 in the absence of any stimulation 
(Figures 6A and 6B). In agreement with this observation, Western blot analysis 
confirmed that Irf4 was expressed in both cytosol and nucleus, with the mutant GC B 
cells expressing several folds more Irf4 than WT cells in the nucleus even in the 
absence of any stimulation (Figure 6C). As for Cbls, in freshly isolated WT GC B cells 
both Cbl and Cbl-b were expressed in the cytosol and nucleus in the absence of CD40 
stimulation, with Cbl more strongly in cytosol and Cbl-b in the nucleus (Figure 6D). 
CD40 and BCR stimulation for one hour significantly diminished Cbl-b and for three 
hours reduced both Cbl-b and Cbl in the nucleus. The stimulation concomitantly 
increased the level of nuclear Irf4 (Figure 6D), suggesting that nuclear Cbl proteins 
eradicate Irf4 in GC B cells.  
 
To determine whether Cbl proteins regulated Irf4 expression by promoting Irf4 
ubiquitination, we co-expressed Irf4 with either Cbl or Cbl-b in 293T cells and 
examined Irf4 association with, and ubiquitination by, Cbl or Cbl-b by 
immunoprecipitation and Western blot analysis. Irf4 associated with, and became 
ubiquitinated by, either Cbl or Cbl-b in 293T cells (Figures 6E and 6F). The 
association of Irf4 with Cbl and Cbl-b in freshly isolated WT GC B cells, as well as its 
ubiquitination in WT but not in Cbl-/- Cbl-b-/- iGC B cells, was confirmed by co-
immunoprecipitation and Western blot hybridization (Figure 6G and 6H). Thus, the 
observed dynamic change of Irf4 expression in GC LZ B cells is at least partly 
regulated by Cbl-dependent Irf4 ubiquitination and degradation.  
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Lack of Cbl ubiquitin ligase activity or increase in Irf4 expression is sufficient 
to impair GC affinity selection 
The above results suggest a hypothesis that the elevated level of Cbls in GC B cells 
removes Irf4 by promoting Irf4 ubiquitination, consequently allowing continuation 
of GC cycle until high affinity BCRs are acquired. If this is the case, we expected that 
inactivation of Cbl ubiquitin ligase activity or increased Irf4 expression in GC B cells 
impairs antibody affinity maturation. To examine whether Cbl ubiquitin ligase 
activity was required for antibody affinity maturation, we bred Cblfl/fl mice to IgCJ-
Cre tg and Cbl-bC373A/C373A mice, the latter expressed a mutant Cbl-b whose ubiquitin 
ligase activity was inactivated by a cysteine to alanine mutation at position 373 of 
the Cbl-b (Oksvold et al., 2008). The resulting Cblfl/fl Cbl-b-/C373A IgCJ-Cre tg (termed 
Cbl-/- Cbl-b-/C373A) mice were immunized with NP-KLH. The development of high 
affinity GC B cells and PCs were examined by flow cytometry and ELISPOT, 
respectively. Cbl-/- Cbl-b-/C373A mice recapitulated GC B cell phenotypes found in Cbl-
/- Cbl-b-/- mice, as they produced a slightly lower number of GC B cells compared to 
Cblfl/fl Cbl-b-/+ IgCJ-Cre tg and WT controls at day 12 after immunization (Figure 7A 
and S9A). In addition, the numbers of high affinity anti-NP (NP8) GC B cells as well 
as anti-NP8 IgG1 secreting PCs were all reduced in the mutant mice relative to the 
controls (Figures 7B, 7C and ES2A).  
 
To determine whether increased Irf4 protein was sufficient to abolish antibody 
affinity maturation, we ectopically expressed Irf4 in WT hematopoietic stem cells by 
a retroviral vector and generated BM chimeras (termed Irf4-MSCV BM mice). 
Expression of the transgenic Irf4 was confirmed by Western blot analysis (Figure 
ES2B). These mice were then immunized with NP-KLH, and selection of high affinity 
NP-binding GC B cells and PCs was analyzed by flow cytometry. Similar to that found 
in Cbl-/- Cbl-b-/- and Cbl-/- Cbl-b-/C373A mice, in IRrf-MSCV BM chimeras the transgene 
Irf4 expressing (Irf4-MSCV) B cells generated a slightly lower number of GC B cells 
at day 12 compared to empty retrovirus (MIGR-MSCV) infected B cells (Figure 7D), 
indicating that Irf4-overexpressing B cells can enter GC reaction. However, the 
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production of high affinity anti-NP8 IgG1 expressing GC B cells was impaired in the 
mutant (Irf4-MSCV, GFP+) but not in WT controls (MIGR-MSCV, GFP+) (Figure 7E). 
The numbers of PCs generated from Irf4-MSCV infected B cells were consistently 
increased as compared to empty vector infected cells (Figure 7F). 
 
Together, these results indicate that lack of ubiquitin ligase activity of Cbls or 
excessive Irf4 expression is sufficient to abolish the development of high affinity GC 
B cells. 
 
DISCUSSION 
Selective expansion of high affinity BCR-expressing B cells in GCs is a critical step in 
antibody affinity maturation. We found that Cbls play an indispensable role in this 
regulation, as ablation of Cbls in GC B cells selectively impaired the development of 
GC B cells expressing high but not low affinity BCRs. Loss of Cbls in GC B cells did not 
significantly alter the efficiency of SHM per se, but rather impeded the clonal 
expansion of high affinity B cells in GCs. Since inactivation of Cbl ubiquitin ligase 
activity was sufficient to recapitulate this GC phenotype, our studies support the 
notion that Cbls define an ubiquitination-dependent regulatory pathway that 
enforces affinity-driven clonal selection of high affinity GC B cells. 
 
It is generally envisioned that high affinity BCRs facilitate clonal expansion and 
selection of GC B cells via two modes of regulation. First, high affinity BCRs may 
drive more vigorous cell proliferation, because they elicit stronger BCR signaling 
than low affinity BCRs. However, this proposition has received conflicting evidence, 
as attenuated rather than enhanced BCR signaling is favorable for GC B cell 
expansion and high affinity BCRs tend to cease GC B cell fate and initiates PC 
differentiation (Khalil et al., 2012; Krautler et al., 2017). As an alternative to the 
signaling role of the BCR in GC affinity selection, high affinity BCRs are thought to 
capture more antigen than BCRs with inferior affinity, thus giving high affinity B 
cells the advantage of competing for the help of Tfh cells, mainly via the increased 
expression of CD40L (Gitlin et al., 2014; Liu et al., 2015). How B cells interpret BCR 
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affinity cues differently since the same signals control both the mitotic and 
differentiation pathways of GC B cells is unclear. In our studies, we found that 
ablation of Cbls expedited GC B cell differentiation, but not proliferation upon CD40 
and/or BCR stimulation. This finding thus puts Cbls at the branch of signaling 
pathway to prevent the B cell differentiation rather than proliferation. In line with 
this view, we observed that the Cbl-/- Cbl-b-/- mutation did not affect CD40 and BCR 
induced mitotic signaling such as AKT, S6K, ERKs, and canonical NF-NB. Instead, it 
resulted in the accumulation of Irf4 protein in GC B cells. We also found that in B 
cells Cbls promote Irf4 ubiquitination. CD40 and BCR stimulation decreased the 
expression of Cbls and conversely increased the expression of Irf4 in GC B cells. 
Finally, ablation of Cbls in GC B cells using ER-Cre inducible system preferentially 
facilitated high affinity B cells to terminate the GC fate and differentiate into PCs. 
Taken together, theses findings lead to a model wherein by clearing Irf4 protein 
rather than regulating the mitotic signaling pathways, Cbls enable CD40 and BCR 
signals to promote GC B cell proliferate without activating the PC differentiation 
program. This regulation can be reversed in high affinity GC B cells in which strong 
CD40 and BCR signaling generated by the high affinity BCRs cue decreases the 
expression of Cbls, leading to increased amount of Irf4 and differentiation of these 
cells into PCs. 
 
The fates of GC B cells and PCs are determined by transcription factors Bcl6, Irf4, 
and BLIMP (Basso and Dalla-Favera, 2015; Shapiro-Shelef and Calame, 2005). 
However, a recent transcriptome study revealed that transcription of Bcl6 is 
abruptly decreased whereas that of Irf4 and pmdr1 is abruptly increased in 
plasmablasts, hence raising a question as to what is tǲǳ that drives the 
transition of this transcriptional network from the equilibrium state of GC B cells to 
that of PCs (Shi et al., 2015). Our data reveal that in WT mice a small population of 
GC B cells downregulated Bcl6 and upregulated Irf4 (Bcl6loIrf4hi). Triggering of 
CD40 and BCR for a short period increased this cell subset, suggesting that these 
cells represent emerging plasmablasts or plasma cell precursors. Development of 
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this subset appeared to be controlled by Cbls, because they were significantly 
increased in the GCs of Cbl-/- Cbl-b-/- mice. In GC B cells, we showed that Cbls 
ubiquitinated Irf4. Strong CD40 and BCR stimulation decreased the expression of 
Cbl proteins and concomitantly increased the expression of Irf4. We therefore 
propose that relief of Irf4 from Cbl-mediated ubiquitination upon strong CD40 
and/or BCR triggering is the earliest PC fate commitment event occurring in the LZ 
GC B cells, preceding the conversion of transcriptomes from the state of GC B cells to 
that of PCs. This of course will not refute the role of CD40 in promoting Irf4 gene 
transcription, which may be compromised in LZ B cells at the Irf4 protein level until 
Cbls are degraded. 
 
Previous studies have shown that selection of high affinity GC B cells depends on the 
transcription factors NFNB, Myc, and Foxo1, in a B cell-intrinsic fashion. Both Myc 
and canonic NFNB are expressed or activated in a small subset of LZ GC B cells 
(Calado et al., 2012; De Silva and Klein, 2015; Dominguez-Sola et al., 2015; Heise et 
al., 2014). Ablation of Myc, rel or relb genes, respectively, in GC B cells results in the 
collapse of the GC reaction, because these factors are required for the maintenance 
of the GC reaction by facilitating LZ to DZ circulation. Foxo1 is required for 
sustaining the DZ program, as inactivation of Foxo1 gene disrupts the expansion of 
DZ B cells possibly by dysregulating the function of the transcription factor Batf 
(Inoue et al., 2017). In contrast to the above regulations, Cbls control GC affinity 
maturation by determining the time when a GC B cell is allowed to enter the PC pool. 
In this regard, Cbls seem to represent a new regulation that controls the exit 
checkpoint of the DZ-LZ cycle, consequently contributing to BCR affinity selection. It 
will be interesting to determine whether this mechanism also contributes to the 
recently described temporal switch in the differential output of memory B cells and 
PCs during the GC reaction (Weisel et al., 2016). 
 
Selection of high affinity B cells occurs in the GC LZ where BCR affinity cues can be 
assessed via interaction with antigen presented on follicular dendritic cells 
18 
(Heesters et al., 2014). Our findings that the expression of Cbls is markedly 
increased in GC LZ compared to DZ B cells at the protein but not at the mRNA level, 
and that CD40 and BCR signals reduce the expression of Cbl proteins, raise an 
interesting question as to how the expression of Cbls is spatially and temporally 
controlled during the GC DZ-LZ cycle. CD40 is known to activate RING-domain 
containing Trafs or cIAPs, both of which regulate their respective downstream 
signaling molecules by ubiquitination (Elgueta et al., 2009). Along this line, at least 
Traf 6 and Traf 2 have been shown to associate with Cbl-b (Elgueta et al., 2009). 
Alternatively, CD40 signal could modulate the translation of Cbl proteins through a 
microRNA dependent mechanism. Consistent with this speculation, it has been 
found that CD40 stimulation enhances the expression of multiple microRNAs among 
which miR155 may influence Cbl-b expression in B cells (Loeb et al., 2012; Vigorito 
et al., 2007). Nevertheless, it will be interesting to investigate whether modulation 
of the Cbl pathway can be used as a strategy to improve the clinical benefit such as 
the efficiency of vaccination in future.   
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Antibodies 
anti-CD4 e450 Ebioscience/Thermo Cat#48-0042-82 
anti-CD8 e450 Ebioscience/Thermo Cat#48-0032-82 
anti-Gr1 e450 Ebioscience/Thermo Cat#48-5931-82 
anti-CD11c e450 Ebioscience/Thermo Cat#48-0114-82 
anti-CD11b e450 Ebioscience/Thermo Cat#48-0112-82 
anti-Ter119 e450 Ebioscience/Thermo Cat#48-5921-82 
anti-F4/80 e450 Ebioscience/Thermo Cat#48-4801-82 
anti-B220 e450 Ebioscience/Thermo Cat#48-0452-82 
anti-B220 PE-CY7 Ebioscience/Thermo Cat#25-0452-82 
anti-GL7 e450 Ebioscience/Thermo Cat#48-5902-82 
anti-GL7 FITC Ebioscience/Thermo Cat#53-5902-82 
anti-IgM PE Ebioscience/Thermo Cat#12-5890-81 
anti-CD23 PE-CY7 Ebioscience/Thermo Cat#5-0232-81 
anti-CD24 PE Ebioscience/Thermo Cat#12-0241-81 
anti-CD93 APC Ebioscience/Thermo Cat#17-5892-82 
anti-CXCR4 PE Ebioscience/Thermo Cat#12-9991-82 
anti-Irf4 PE Ebioscience/Thermo Cat#12-9858-80 
anti-B220 FITC Ebioscience/Thermo Cat#11-0452-82 
Strepavidin PE-CY7 Ebioscience/Thermo Cat#24-4317-82 
anti-CD86 Ebioscience/Thermo Cat#17-0862-81 
anti-phospho-S6(S235/S236) Ebioscience/Thermo Cat#12-9007-42 
anti-B220 APC Biolegend Cat#103212 
anti-CD38 APC Biolegend Cat#102712 
Alexa647 anti-BrdU Biolegend Cat#364108 
anti-  Biolegend Cat#407306 
anti-Fas PE BD Cat#554258 
anti-Fas PE-CY7 BD Cat#557653 
anti-IgG1 FITC BD Cat#553443 
anti-IgD FITC BD Cat#553439 
anti-CD21/CD35 FITC BD Cat#553818 
Alexa647 anti-Bcl6 BD Cat#561525 
anti-CD138 PE BD Cat#553714 
anti-CD35 Biotin BD Cat#553816 
anti-CD138 e450 BD Cat#562610 
Alexa647 anti-AKT(p473) BD Cat#560343 
Alexa647 anti-ERK1/2(pT202/pY204) BD Cat#612593 
Purified anti-CD40 ENZO Cat#ALX-805-046-
C100 
Purified anti-IgMF(ab)2 Jasckson 
ImmunoResearch 
Cat#115-006-020 
anti-mouse Cbl Santa Cruz Cat#SC-170 
anti-mouse Irf4 Santa Cruz Cat#SC-6059 
anti-LAMINB Santa Cruz Cat#SC-374015 
anti-HA Santa Cruz Cat#SC-805 
HRP conjugated anti- -ACTIN Abcam Cat#AB49900 
anti-Flag Sigma Cat#F1804-50UG 
anti-Goat IgG HRP Santa Cruz Cat#SC-2020 
anti-Rabbit IgG HRP Cell Signaling Cat#7074P2 
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anti-Mouse IgG HRP Cell Signaling Cat#7076P2 
anti-Mouse Cbl-b Cell Signaling Cat#9498S 
anti-Mouse IgG1 HRP Thermo Cat#A10551 
anti-Mouse IgM HRP Thermo  Cat#M31507 
anti- -Tubulin Sigma Cat#T4026-.2ML 
PNA Biotin Vector Cat#B-1075 
PNA FITC Vector Cat#FL-1071 
Strepavidin Alexa488 Thermo Cat#S-32354 
Strepavidin Alexa568 Thermo Cat#S-11226 
Donkey anti-Goat Alexa594 Thermo Cat#A-11058 
Goat anti-Rabbit Alexa568 Thermo Cat#A-11036 
Bacterial and Virus Strains  
 Thermo Cat#18265017 
Stbl2TM competent cells Thermo Cat#10268019 
Stbl3TM competent cells Thermo Cat#C737303 
Chemicals, Peptides, and Recombinant Proteins 
5-Fluorouracil Sigma Cat#F6627-5G 
MG132 Sigma Cat#C2211 
NHS-Biotin Thermo Cat#21335 
Recombinant mouse IL-4 protein R&D Cat#404-ML-050 
Recombinant mouse SCF protein R&D Cat#455-MC-050 
Recombinant mouse IL-6 protein R&D Cat#406-ML-025/CF 
Recombinant mouse IL-3 protein R&D Cat#403-ML-050/CF 
Celltrace Proliferation dye Ebioscience/Thermo Cat#C34557 
SYBR Green qPCR Master Mix Life Technology Cat#4309155 
NP4-BSA Bioresearch 
Technologies 
Cat#N-5050L-10 
NP30-BSA Bioresearch 
Technologies 
Cat#N-5050L-10 
rProtein G Agarose  Thermo Cat#15920-010 
Sheep Red Blood Cells Innovative Research Cat#IC100-0210 
NP36-KLH Bioresearch 
Technologies 
Cat#N-5060-25 
1-StepTM Ultra TMB-ELISA Substrate Solution Thermo Cat#34029 
Critical Commercial Assays 
FITC-BrdU kit BD Cat#559619 
Nuclear Extract Kit Active motif Cat#40010 
AEC Substrate Set BD Cat#551951 
B cell negative selection kit Stem cell Cat#19854 
CaspaseGlowTM FITC Active Caspase Staining Kit Biodivision Cat#A10551 
Experimental Models: Cell Lines 
293T cell line Laboratory of Gu  
Phoenix cell line Laboratory of Gu  
40LB cell line Laboratory of D. 
Kitamura 
 
Experimental Models: Organisms/Strains 
Cbl flox/flox conditional knockout mice Laboratory of Gu  
Cbl-b germline knockout mice Laboratory of Gu  
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-cre mice Laboratory of K. 
Rajewsky 
 
CblbC373A mutation mice Laboratory of W. 
Langdon 
 
C57BL/6 mice The Jackson 
Laboratory 
Stock#000664 
B6.SJL mice The Jackson 
Laboratory 
Stock#002014 
Rag1-/- mice The Jackson 
Laboratory 
Stock#002216 
Oligonucleotides 
Cbl-b qPCR primer 
)RUZDUG¶-GGGGACGGCAATATCCTACAG-¶ 
5HYHUVH¶-TATAGCTCCGCCCATCAGGA-¶ 
IDT N/A 
Cbl qPCR primer 
Forward: ¶-CTCCTCCTTTGGCTGGTTGT-¶ 
5HYHUVH¶-TTCTCCGAGGGAATGGTTTGG-¶ 
IDT N/A 
Acida qPCR primer 
)RUZDUG¶-AAGGGACGGCATGAGACCTA-¶ 
5HYHUVH¶-AGCCAGACTTGTTGCGAAGG-¶ 
IDT N/A 
Irf4 qPCR primer 
)RUZDUG¶-AGGTCTGCTGAAGCCTTGGC-¶ 
Reverse: ¶-CTTCAGGGCTCGTGGTC-¶ 
IDT N/A 
E-Actin qPCR primer 
)RUZDUG¶-CGATGCCCTGAGGCTCTT-¶ 
5HYHUVH¶-TGGATGCCACAGGATTCCA-¶ 
IDT N/A 
Gapdh qPCR primer 
)RUZDUG¶-TCGTCCCGTAGACAAAATGGT-¶ 
5HYHUVH¶-CGCCAAATACGGCCAAA-¶ 
IDT N/A 
Bcl6 qPCR primer 
Forward: ¶-TTTCTGGTTCACTGGCCTTGA-¶ 
5HYHUVH¶-CCTGCAGATGGAGCATGTTG-¶ 
IDT N/A 
Bach2 qPCR primer 
)RUZDUG¶-AGTAAGAACCGCATTGCAGC-¶ 
5HYHUVH¶-TTCCTTCTCGCACACCAGTT-¶ 
IDT N/A 
Recombinant DNA 
Mouse Cbl-b sequence-verified cDNA Laboratory of Gu N/A 
Mouse Cbl sequence-verified cDNA Laboratory of Gu N/A 
Mouse Irf4 sequence-verified cDNA Laboratory of Gu N/A 
HA-UB expression vector Dr.Chen N/A 
pCDNA vector Invitrogen Cat#V790-20 
MIGR1-MSCV retro-expression vector Addgene Plasmid#27490 
p3xFlag-CMVTM 7 vector Sigma Cat#E7533 
-GFP fusion vector Dr.Huang N/A 
Software and Algorithms 
Prism(6.0-7.0) Graphpad  
FlowJo(v9-10) Treeview  
Volocity PerkinElmer  
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CONTACT FOR REAGEND AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to 
and will be fulfilled by the Lead Contact, Hua Gu (hua.gu@ircm.qc.ca) 
 
EXPERIMENTAL MODLE AND SUBJECTED DETAILS 
 
Mice 
C57BL/6 mice, B6.SJL mice, PMT mice and Rag1-/- mice were from The Jackson 
Laboratory. Cbl  floxed and Cbl-b-/- mice were described previously (Chiang et al., 
2000; Naramura et al., 2002). To generate Cbl-/- Cbl-b-/- mice, Cbl floxed/floxed 
(Cblfl/fl) and Cbl-b-/- mice were crossed to IgCJ1-Cre transgenic mice kindly provided 
by S. Casola and K. Rajewsky (Casola et al., 2006). Cbl-bC373A mice were described 
previously (Oksvold et al., 2008). Animal experimentation was done in accordance 
with the Canadian Council of Animal Care and approved by the Institut de 
Recherches Cliniques de Montreal (IRCM) Animal Care Committee. 
 
METHOD DETAILS 
Plasmids, cell lines and culture 
cDNA encoding Irf4 was PCR amplified and cloned into plasmid p3xFlag-CMVTM 7 
expression vector. cDNAs encoding Cbl and Cbl-b were separately cloned into 
pCDNA vector. For the construction of Irf4 overexpression vector, cDNA encoding 
Irf4 was cloned into MSCV-MIGR-GFP retroviral vector. INB-GFP fusion protein 
retrovirus expression vector was kindly provided by Dr. F. Huang. Hemagglutinin 
(HA)-tagged ubiquitin vector was a gift from Dr. R. Chen. To prepare retrovirus, 
Phoenix cells were transfected with the appropriate amount of retroviral vector and 
package plasmids (30 Pg) by Calcium precipitation, according to previous 
publication (Han et al., 2010). For 40LB culture, naïve WT and Cbl-/- Cbl-b-/- B cells 
were purified from WT (C57BL-6 or C57BL/6 Mb1-Cre tg) and Cblfl/fl Cbl-b-/- Mb1-
Cre tg) mice by a magnetic column (StemCell Technologies), respectively. GC B cells 
were purified by FACS sorting. Purified B cells were seeded onto irradiated (900 
29 
RAD) 40LB cells described previously (Nojima et al., 2011). B cells were cultured at 
37oC for five days, trypsinized and replated onto a fresh 40LB plate for two more 
days before being subjected to FACS analysis.  
 
Immunization and GC B cell purification 
To test T-dependent antibody responses and germinal center reaction, 6 to 10 
week-old mice were immunized with either 109 sheep red blood cells (SRBCs) 
(Innovative Research) in PBS or NP36-KLH (BioSources) precipitated in alum 
adjuvant  (Imject Alum, ThemoScientific) by i.p. injection. Mice were analyzed at 
different days after immunization. To examine the expression of Cbls in GC B cells, 
SRBC immunized mice were sacrificed at day 8 and B cells were enriched by a 
magnetic column, stained with anti-B220, CD138, GL7, and Fas. GC (B220+ GL7hi 
Fashi) B cells were then purified by FACS sorting on a FACS Aria or Moflo. To obtain 
a large quantity of GC B cells for in vitro stimulation and culture, mice were 
sequentially immunized at day 0 (1x108 SRBCs) and day 5 (1x109 SRBCs) by i.v. 
injection. Immunized mice were sacrificed at day 12, B cells were enriched by a 
magnetic B cell enrichment column (StemCell) and subsequently sorted as B220+ 
CD138- GL7+ cells. Purity of the isolated GC B cells was confirmed by FACS analysis 
and was shown to be more than 95% pure for cell surface markers B220+ GL7hi Fashi 
(Figure ES2C). 
 
Flow cytometric analysis 
Total splenic cells or splenic B cells were resuspended in FACS buffer (5%BSA in 
PBS (PH=7.2)) and stained with the corresponding antibodies on ice for 30 min. 
Cells were washed twice with FACS buffer and then subjected to analysis on a BD 
Fortessa or Cyan or to cell sorting on a FACS Aria or Moflo. The following antibodies 
were used for the staining: anti-B220, anti-GL7, anti-CD11c, anti-CD11b, anti-Gr1, 
anti-F4/80, anti-NK1.1, anti-Irf4, anti-IgO, anti-TCRE, anti-CD3H, anti-CD86, and anti-
CD38 (eBioscience); anti-Fas, anti-CD138, anti-Bcl6, anti-CXCR4, anti-IgG1, anti-IgD 
(BD Pharmingen). High affinity and total NP-binding B cells and plasma cells were 
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stained with NP8-PE, NIP5-PE, and NP38-PE (BioSearch), respectively. Specificity of 
NIP5ȂAPC and NP38-PE to NP-specific but not to carrier protein specific BCRs was 
confirmed using GC B cells from OVA or NP-OVA immunized mice (Figure ES2D). To 
analyze nuclear proteins Bcl6 and Irf4, total splenic cells were first stained for B220, 
Fas, and GL7, fixed and permeabilized with FOXP3 staining buffer according to the 
manufacturerǯȋȌǡ-Bcl6 and Irf4. 
For cell cycle analysis, mice were injected intravenously with 1 mg of BrdU (BD 
Pharmingen) in DPBS. Cells were then surface stained with corresponding 
antibodies, and BrdU labeled cells were stained using an anti-BrdU kit according to 
the manufacturerǯs protocols (BD Pharmingen).  
 
qPCR and RNA-Seq analysis 
To study the gene expression profiling, naïve B cells and GC (B220+CD138-GL7+Fas+) 
B cells from wildtype and Cbl-/- Cbl-b-/- mice were purified by FACS sorting. Total 
RNAs from sorted cells (pooled from three mice) was extracted using an RNEasy 
Mini Kit (Qiagen), and reversely transcribed into cDNA using a Reverse-
Transcription kit (Invitrogen) according to manufacturerǯs instructions, 
respectively.  
 
RNA-seq was performed using the Illumina TruSeq Stranded mRNA Kit according to ǯina HiSeq 2000 sequencer. Read quality was 
confirmed using FastQC v0.10.1. Read alignment was performed using TopHat 
v2.0.10 on the mouse GRCm38/mm10 genome. Differential expression analysis was 
performed with DESeq2 from the raw alignment counts calculated with 
featureCounts. Differentially expressed genes were defined as genes with a 
|logFC(counts)|>2 and counts > 500 in both experiments. Shown are log2 (counts) 
expression values of 982 downregulated and 51 upregulated genes in Cbl-/- Cbl-b-/- 
than in WT GC B cells. 
 
A SYBR Green PCR mix (Thermo Scientific) and gene-specific primers were used for 
quantitative RT-PCR analysis (20-50 ng cDNA per reaction). All reactions were done 
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in triplicates with ViiA7-96 Real Time PCR System (Applied Biosystems). Results 
were analyzed by the change-in-threshold (2-ȟȟ) method, with E-Actin or GAPDH as ǮǯǡǤ 
 
Immunofluorescence 
Spleens were embedded in optimum cutting temperature compound (Sakura) and 
flash-frozen in liquid nitrogen. Tissue sections were cut on Cryotome (Leica), fixed 
in ice-cold acetone (Sigma), blocked with PBS+5%BSA for 1 hour at 25°C, and 
stained with anti-Cbl (Santa Cruz), anti-Cbl-b (Santa Cruz), anti-CD35 (BD 
Pharmingen), anti-B220 (BD Pharmingen), and/or PNA (VectorLab), in different 
combination. The following secondary antibodies were used to detect primary 
antibodies: anti-Rabbit Alexa-568 (Invitrogen), Streptavidin Alexa-488 (Invitrogen), 
Streptavidin Alex-633 (Invitrogen). Images were acquired on a Zeiss LSM700 or 710 
confocal microscope. 
 
For intracellular staining of Irf4, GC B cell or stimulated GC B cells were purified by 
FACS sorting. Cells were fixed with 4% PFA, permeabilized with 0.1% Triton X-100, 
blocked with PBS+5% BSA, and stained with anti-Irf4 (Santa Cruz), followed by anti-
Goat Alexa 568 secondary antibody. Cell nucleus was counter stained with DAPI. 
Images were acquired on a Zeiss LSM710 confocal microscope. 
 
Ig VH 186.2 gene isolation and DNA sequencing 
GC (B220+ Fashi GL7hi IgO+ or B220+ Fashi GL7hi NP38-PE+) B cells were isolated by 
FACS from three NP36-KLH immunized WT and Cbl-/- Cbl-b-/- mice, respectively, at 
day 14 after immunization. Genomic DNA was extracted from the sorted cells using 
a QuickExtractTm DNA Extraction Solution (Epicentre). For VH186.2 sequencing, 
VH186.2-JH2 joints were amplified from genomic DNA by PCR using specific primers    ?ǯ   H ? ? ?Ǥ ?    ?ǯ   H2 gene according to a previous 
protocol (Dominguez-Sola et al., 2012). PCR products were gel extracted and cloned 
into a TOPO vector (Invitrogen). High quality traces were analyzed using MacVector 
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for base pair mismatches and deletions as compared to the germline VH186.2 gene 
sequence. Only mismatches mutations in the productive VH186.2-JH2 joints were 
counted as mutations. Ig VH sequences were analyzed using the IMGT/V-QUEST 
system to identify the W33L mutation. Primers used were: VH 186.2:  ?ǯ-
AGCTGTATCATGCTCTTCTTGGCA - ?ǯ; JH2:  ?ǯ-AGATGGAGGCCAGTG AGGGAC - ?ǯǤ 
 
Enzyme-linked immunospot (ELISPOT) assay and enzyme-linked 
immunosorbent assay (ELISA) 
Total splenic or bone marrow cells were cultured at 37°C in antigen pre-coated 96-
well Multiscreen-HA filter plates (Millipore) overnight. Spots of antibody secreting 
cells were stained with rabbit anti-mouse IgM or IgG1 antibodies conjugated to 
horseradish peroxidase (Invitrogen), and then developed by addition of AEC 
substrate (BD Pharmingen). Plates were washed extensively and spots were 
counted on a dissect microscopy. The antigens used for plate coating were NP4-OVA 
and NP30-OVA, respectively. Anti-NP ELISAs were performed as described 
previously (Jang et al., 2011).  
 
Immunoprecipitation and Immunoblot analysis. 
Cells were lysed in TNE buffer (50mM Trise; 140mM NaCl; 5mM EDTA; 0.5% SDS), 
and immunoblotting was performed following standard procedures. For 
immunoprecipitation, proteins were immunoprecipitated by incubation of cell 
lysate overnight at 4
precipitate the protein-antibody complexes by incubating with protein G agarose 
(Invitrogen) for another 1 hour at 4°C. Immunoprecipitates were washed four times 
with TNE buffer, boiled in 40 Pl loading buffer and immunoblotted to a PVDF 
membrane for Western blot analysis. The following antibodies were used for 
biochemical study: anti-IgM F(ab)2 (BioSource); anti-CD40 (ENZO); anti-Cbl 
(SantaCruz); anti-Irf4 (SantaCruz); anti-Lamin B (SantaCruz); anti-BLIMP1 
(SantaCruz); anti-HA (SantaCruz); anti-Cbl-b (Cell signaling); anti-E
anti-Flag (Sigma). Horseradish-peroxidase-conjugated goat anti-rabbit, goat anti-
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mouse or donkey anti-goat antibody was used as a secondary antibody, respectively. 
Membranes were developed with an enhanced chemiluminescence detection system 
(GE Healthcare). 
 
A Nuclear extraction kit was used to fractionate nuclear and cytoplasmic proteins 
according to manufacturerǯs (Active motif).  
 
Bone marrow and Cbl-/- Cbl-b-/-ERCre B cell chimeric mice 
To generated Irf4 over-expression or INB-GFP expressing bone marrow chimeric 
mice, retroviral stocks were prepared by transfection of Phoenix cells with MSCV-
MIGR1 (empty vector), Irf4-MSCV or MSCV-INB-GFP retroviral vector together with 
the packaging vector pCL-Eco by the standard calcium transfection (Han et al., 
2010). Viral supernatants were collected 48 h and 72 h after the transfection, 
respectively. To obtain bone marrow stem cells, donor mice were treated with 5-FU 
(5 mg/mouse, i.p.). Four days later, bone marrow stem cells were collected and 
cultured under optimal stem cell culture condition. After two-rounds retroviral 
spin-infections, bone marrow cells were adaptively transferred into lethally 
irradiated (10 Gy) Rag1-/- recipient mice. Six weeks later, mice were subjected to 
different immunization regimens.  
 
To generate Cbl-/- Cbl-b-/-ERCre chimeric mice, 1.5x107 splenic B cells from either Cbl-
b-/- ER-Cre tg (control) or Cblfl/fl Cbl-b-/- ER-Cre tg (Cbl-/- Cbl-b-/-ERCre) mice were 
transferred into PMT mice by i. v. injection. Chimeric mice were immunized i.p. with 
NP-KLH in Alumjet adjuvant the next day (day 0), and given daily tamoxifen 
(200Pg/g body weight) from day 7-10 by oral administration. Mice were sacrificed 
at day 12, and splenic cells were subjected for FACS analysis. High affinity NP (NIP5-
binding) GC B cells and PCs were identified by cell surface and intracellularly 
staining, respectively, using NIP5-PE in combination with surface markers for GC B 
cells (B220+ GL7hi Fashi) or PCs (B220-/lo CD138+Lin-). 
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Cell division and differentiation assay  
Purified B cells were labeled with CellTrace fluorescent according to manufacturerǯ
instructions. Cells were cultured on 40LB feeder for five days and then labeled with 
CellTrace fluorescent according to manufacturerǯs. Naïve Cbl-/- Cbl-b-/- B 
cells were isolated from Cblfl/fl Cbl-b-/- Mb1-Cre tg mice. Labeled cells were plated on 
a fresh 40LB plate and cultured for two more days. Cultured B cells were harvested 
and cell proliferation was analyzed on a FACS. To examine culture B cell 
differentiation to PCs, cells were stained with B220, CD138, and Irf4. Irf4 and CD138 
positive cells in each cell division were analyzed on a FACS. 
 
STATISTICAL ANALYSIS 
Statistical analyses were performed with a two-ǡǯ-test or 	ǯ, with GraphPad Prism V7 software. A P value <0.05 was 
considered statistically significant. 
 
 
 
 
 
FIGURE LEGENDS  
Figure 1. Differential Expression of Cbl and Cbl-b in GC DZ and LZ B Cells 
(A) qPCR analysis of Cbl and Cbl-b mRNA expression in WT naïve and GC B cells. 
Results were normalized to actin. Expression in naïve B cells was arbitrarily defined 
as 1. Data reflect mean ± SEM of three independent experiments. p<0.05 (unpaired 
Student¶s t tests). 
(B) Western blot analysis of Cbl and Cbl-b expression in WT none-GC B and GC B 
cells. Shown are the results of one representative experiment out of two. 
(C) Immunofluorescent staining of Cbl and Cbl-b in GC DZ and LZ. GC B cells and the 
LZ were stained by PNA (green) and anti-CD35 (blue), respectively. Cbl and Cbl-b 
were visualized in red (Scale bar, 35Pm). Shown are the results of one 
representative out of five individual GCs. 
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(D) Western blot analysis of Cbl and Cbl-b expression in DZ and LZ GC B cells. DZ 
and LZ GC B cells were purified by FACS as B220+GL7hiFashiCXCR4hiCD86lo and 
B220+GL7hiFashiCXCR4loCD86hi B cells, respectively. Shown are the results of one 
representative experiment out of two. 
 
Figure 2. Impaired Antibody Affinity Maturation in Cbl-/- Cbl-b-/- Mice  
(A) Kinetics of serum total anti-NP30 antibody titers of IgM and IgG1 isotypes. 
(B) The kinetics of serum high affinity anti-NP4 antibody titers of IgM and IgG1 
isotypes. 
(C) Antibody affinity maturation of IgG1 antibody. The maturation index is defined 
by the ratios of anti-NP4 vs anti-NP30 antibody titers.  
(D) ELISPOT analysis of splenic ASCs against NP30 or NP4-BSA antigen at day 14 
after immunization.  
(E) Developmental kinetics of GC B cells in WT and Cbl-/- Cbl-b-/- mice after NP-KLH 
immunization. Shown are contour maps (top panel) of GC B cells at day 8 and the 
statistics (bottom bars) of GC B cell numbers postimmunization. 
(F) Analysis of apoptotic GC B cells. Apoptotic GC B cells were visualized by anti-
active form Casp staining. Shown are contour plots (left panel) and statistical (right 
bars) of Casp+ GC B cells among total B220+GL7hiFashi B cells.  
(G) Defective development of high affinity BCR expressing GC B cells in Cbl-/- Cbl-b-/- 
mice. Shown at the top panel are the gating strategy for splenic B220+NP8-binding B 
cells and IgG1+CD38- GC B cells among the gated B220+NP8+ cells. Bottom: Statistics 
of high affinity (NP8-binding) IgG1 GC B cells in WT and Cbl-/- Cbl-b-/- mice.  
Data are mean± SEM (A-G) and are representative of two or three independent 
experiments with at least four mice per group. * p<0.05; ** p<0.001; *** p<0.0001 
(unpaired Student¶s t test). 
 
 
Figure 3. Impaired Selection of High Affinity BCRs but not SHM in Cbl-/- Cbl-b-/- 
Mice 
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(A) Pie presentation of the frequency of SHM in VH186.2 genes. VH186.2 genes with 
different numbers of SHM are shown in different degrees of shade (right). The total 
numbers of VH genes analyzed are indicated in the centers of the pies.  
(B) Frequency of replacement vs silent mutations in VH186.2 genes. Each dot 
represents data from one individual VH186.2 gene.  
(C) Representation of VH186.2 clones with W33L mutation. The number of W33L 
clones among VH186.2 sequences is shown in the center of pie chart and was 	ǯǤ **p<0.001. Data are from pooled five mice each 
group.  
(D) Ratios of replacement vs silent (R/S) mutations in VH186.2 coding genes.  
(E) Development of NIP5 and NP38-binding GC B cells at different time points of GC 
reaction. Shown (top panel) are flow cytometric analyses of splenic NP38 or NIP5-
binding cells in gated 220+ GL7hi Fashi GC B cells at day 8 and day 14 post NP-KLH 
immunized. Bottom left and middle: statistics of NP38 and NIP5-binding GC B cells at 
day 8 and 14 after immunization, respectively. Bottom right: Percentages of high 
affinity NP (NIP5-binding) GC B cells among total NP specific (NP38-binding) GC B 
cells at day 8 and day 14 after immunization. Data are mean± SEM (E) and are 
representative of two independent experiments with five mice per group. ** 
p<0.001; *** p<0.0001 (unpaired Student¶s t test).  
 
Figure 4. Expedited PC Differentiation of High Affinity GC B Cells in the 
Absence of Cbls 
(A) In vivo newly generated PCs identified by BrdU labeling assay. Shown are flow 
cytometric (left) and statistics analyses (right) of splenic newly generated PCs after 
24 hours BrdU labeling, identified as Lin-BrdU+CD138+ cells.  
(B) The in vivo rates of PC genesis presented as the total numbers of newly 
generated PCs either per spleen (left) or per hour in the spleen (right).  
(C) Flow cytometric analyses of total (top panel), and NIP5-binding (bottom panel) 
GC B cells at day 12 without (left) or with ER-Cre mediated Cbl ablation (right). 
Statistics (right) are shown as bars.  
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(D) In vitro PC differentiation of naïve WT and Cbl-/- Cbl-b-/- B cells from Cblfl/fl Cbl-b-
/- Mb1-Cre tg mice in 40LB feeder cell culture. Shown are flow cytometric (left) and 
statistical (right) analyses of (CD138+B220hi/lo) PCs/plasma blast-like cells.  
(E) Comparison of In vitro differentiation of freshly isolated WT and Cbl-/- Cbl-b-/- 
(Lin-B220+ GL7hi) GC B cells. Purities of the isolated GC B cells are shown in Figure 
S9B). Shown are flow cytometric (left) and statistical (right) analyses of plasma 
blast-like (B220+CD138hi) cells generated in the culture. 
(F) Cell division dependent B-cell differentiation to PCs in 40LB feeder culture 
system. Shown are dot plots (left) and histogram analyses (right) of Irf4 expression 
in cell divisions 1st, 2nd, 3rd, and 4th WT or Cbl-/- Cbl-b-/- B cells (Cblfl/fl Cbl-b-/- Mb1-
Cre tg) identified by Cell Trace dilution.  
Data are mean± SEM (A-F) and are representative of two or three independent 
experiments with at least four mice per group. * p<0.05; ** p<0.001 (unpaired 
Student¶s t test). 
 
Figure 5. Post-Transcriptional Regulation of GC Differentiation Program by 
Cbls 
 (A) qPCR analysis of GC B cell and PC identity genes in WT and Cbl-/- Cbl-b-/- GC B 
cells. Data were from FACS purified splenic B220+ GL7hi Fashi GC B cells pooled from 
3x WT and Cbl-/- Cbl-b-/- mice at day 8 after SRBC immunization.  
(B) Comparison of the expression of protein synthesis and secretion related genes 
which are upregulated in PCs in WT and Cbl-/- Cbl-b-/- GC B cells based on RNA-seq. 
Shown are the folds of increased expression in Cbl-/- Cbl-b-/- relative to WT GC B 
cells   
(C) Western blot analysis of Irf4 in WT and Cbl-/- Cbl-b-/- B220+ GL7hi CD138- GC B 
cells GC B cells.  
(D and E) Flow cytometric analyses of Irf4 vs Bcl6 expression in GC B cells without 
(D) or with (E) anti-CD40 and BCR stimulation. Shown are contour maps (top panel) 
and statistics (bottom panel) of Irf4hi Bcl6lo and Bcl6hi cells among total gated B220+ 
GL7hi Fashi GC B cells.  
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(F) Western blot analysis of Irf4 expression in WT and Cbl-/- Cbl-b-/- B220+GL7hi 
CD138- GC B cells with or without anti-CD40 and BCR stimulation.  
Data are mean ± SEM (A, D, E) and are representative of two or three independent 
experiments (A, C, D, E, F) with at least four mice per group. ** p<0.001; *** 
p<0.0001 (unpaired Student¶s t test). 
 
Figure 6. Regulation of Nuclear Irf4 Ubiquitination and Expression by Cbls 
 (A and B) Confocal microscopic analysis of cytosolic and nuclear Irf4 in WT and Cbl-
/- Cbl-b-/- GC B cells without (A) or with (B) anti-CD40 and BCR stimulation. The 
statistical analyses show the percentages of nucleus vs total IRrf4. Each dot 
represents one cell.  
(C) Western blot analysis of nuclear vs cytosolic Irf4 in WT and Cbl-/- Cbl-b-/- B220+ 
GL7hi CD138- GC B cells before and after anti-CD40 and BCR stimulation.  
(D) Asymmetric expression of Cbl and Cbl-b vs Irf4 proteins in WT B220+ GL7hi 
CD138- GC B cells before and after CD40 and BCR stimulation.  
(E) Co-immunoprecipitation and Western blot analysis of Cbl and Cbl-b association 
with Flag tagged Irf4 (Irf4-Flag).  
(F) Irf4 ubiquitination by Cbl or Cbl-b. Shown are Western blot analyses of 
ubiquitinated Irf4-Flag immunoprecipitated from 239T cells cotransfected with 
either Cbl or Cbl-b.  
(G) Association of Irf4 with Cbl or Cbl-b in freshly isolated WT GC B cells.  
(H) Ubiquitination of Irf4 in WT and Cbl-/- Cbl-b-/- in vitro generated GC (iGC) B cells.  
Data are mean± SEM (A-B) and are representative of two independent experiments 
(A-G). ** p<0.001; *** p<0.0001 (unpaired Student¶s t test). 
 
Figure 7. Impaired Development of High Affinity GC B Cells in Cbl-/-  
 Cbl-b-/C373A or MSCV-Irf4 BM Chimeric Mice 
 (A-C) Impaired GC affinity maturation in Cbl-/- Cbl-b-/C373A mice as compared to WT 
and Cbl-/- Cbl-b-/+ IgCJ-Cre tg controls (day 12 after NP-KLH immunization). (A) Dot 
plots (left) and statistical (right) analyses of Fas+ GL7+ GC B cells among gated 
39 
splenic B220+ cells. (B) Flow cytometric (left) and statistical (right) analyses of high 
affinity (NP8-binding) GC B cells among total B220+ cells. Shown are the gating 
strategy of splenic B220+NP8-binding B cells (top left panel), high affinity NP specific 
IgG1+CD38- GC B cells (bottom left panel), and statistics of high affinity NP binding 
GC B cells. (C) The statistics of splenic total (anti-NP30-binding antibody) and high 
affinity (NP4Ȃbinding antibody) secreting plasma cells (ASCs).  
(D-F) Ectopic expression of Irf4 abolishes high affinity antibody producing GC B cell 
development in MSCV-Irf4 BM chimeric mice after NP-KLH immunization (day 12). 
WT BM stem cells were transduced with either MIGR-MSCV-GFP (empty) or MSCV-
GFP-Irf4 retroviral vector and used to generate BM chimeras. (D) Dot plots (left) 
and statistical (right) analyses of Fas vs GL7 staining of gated B220+ IgD-/lo splenic 
GC B cells. (E) Contour plots (top) and statistical (bottom) analyses of splenic high 
affinity (NP8-binding) IgG1+CD38- GC B cells in BM chimeras with (GFP+) without 
(GFP-) retrovirus infection. (F) Histogram analysis of B220-CD138+ splenic PCs 
among GFP+ Linage- splenocytes in empty MIGR-MSCV and Irf4-MSCV infected BM 
chimeras.  
Data are mean ± SEM (A-F) and are representative of two or three independent 
experiments with at least five mice per group. * p<0.05; ** p<0.001 (unpaired 
Student¶s t test). 
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